If your email program has trouble displaying this email, view as a webpage.

FDA Office of Minority Health and Health Equity

April 18, 2023

Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals. This action includes authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for all doses administered to individuals 6 months of age and older, including for an additional dose or doses for certain populations. The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.

Related Information

• Pfizer-BioNTech COVID-19 Vaccines
• Moderna COVID-19 Vaccines
• COVID-19 Vaccines
• Emergency Use Authorization for Vaccines Explained

Visit the FDA OMHHE website and follow us on Twitter at @FDAHealthEquity 
"Creating a world where health equity is a reality for all."
www.fda.gov/HealthEquity